Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial

Kura Oncology (KURA) and Kyowa Kirin (KYKOF) announced dosing of the first patient in a cohort of the KOMET-007 clinical trial. This cohort evaluates ziftomenib, a once-daily, investigational oral menin inhibitor, combined with cytarabine and daunorubicin as well as quizartinib, for patients with newly diagnosed acute myeloid leukemia. Despite recent advances, including regulatory approvals of FLT3 inhibitors such as quizartinib, patients with FLT3/NPM1 co-mutations face a high risk of relapse and limited durable treatment options. Ziftomenib is the only menin inhibitor to have received Breakthrough Therapy Designation by the Food and Drug Administration for the treatment of adult patients with relapsed or refractory NPM1-mutated AML.